China SXT Pharmaceuticals Inc Total Assets
China SXT Pharmaceuticals Inc total assets. Based on the latest financial reports, China SXT Pharmaceuticals Inc (SXTC) holds total assets worth $34.75 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see SXTC company net worth for the company's overall valuation and market capitalisation.
Total Assets of China SXT Pharmaceuticals Inc (2016–2026)
Total assets of China SXT Pharmaceuticals Inc from 2016 to 2026. This chart illustrates how China SXT Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data. See current stock price of China SXT Pharmaceuticals Inc for real-time trading data and today's change.
China SXT Pharmaceuticals Inc - Asset Composition Analysis
China SXT Pharmaceuticals Inc Total Assets Breakdown (March 2026)
China SXT Pharmaceuticals Inc total assets breakdown as of March 2026. China SXT Pharmaceuticals Inc's total assets of $34.75 Million consist of 99.3% current assets and 0.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 81.1% |
| Accounts Receivable | $3.23 Million | 9.3% |
| Inventory | $2.96 Million | 8.5% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $6.33K | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2016–2026)
This chart illustrates how China SXT Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore China SXT Pharmaceuticals Inc (SXTC) liquidity to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: China SXT Pharmaceuticals Inc's current assets represent 99.3% of total assets in 2026, an increase from 91.1% in 2016.
- Cash Position: Cash and equivalents constituted 81.1% of total assets in 2026, up from 0.2% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 9.3% of total assets.
China SXT Pharmaceuticals Inc Competitors by Total Assets
Key competitors of China SXT Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
GALDERMA GROUP AG
NYSE:GALDY
|
USA | $13.39 Billion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Galderma Group N
SW:GALD
|
Switzerland | CHF12.88 Billion |
|
Enzymatica publ AB
ST:ENZY
|
Sweden | Skr149.24 Million |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥13.98 Billion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥17.01 Billion |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518
|
China | CN¥13.68 Billion |
|
Walvax BioTech
SHE:300142
|
China | CN¥10.50 Billion |
China SXT Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.93 | 3.54 | 1.31 |
| Quick Ratio | 7.25 | 3.40 | 1.16 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $30.16 Million | $15.28 Million | $2.78 Million |
China SXT Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between China SXT Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.11 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | 60.4% |
| Total Assets | $34.75 Million |
| Market Capitalization | $453.91K USD |
Valuation Analysis
Below Book Valuation: The market values China SXT Pharmaceuticals Inc's assets below their book value (0.01x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: China SXT Pharmaceuticals Inc's assets grew by 60.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for China SXT Pharmaceuticals Inc (2016–2026)
The table below shows the annual total assets of China SXT Pharmaceuticals Inc from 2016 to 2026.
| Year | Total Assets | Change |
|---|---|---|
| 2026-03-31 | $34.75 Million | +60.43% |
| 2025-03-31 | $21.66 Million | -6.33% |
| 2024-03-31 | $23.13 Million | -21.75% |
| 2023-03-31 | $29.55 Million | -11.90% |
| 2022-03-31 | $33.55 Million | -2.90% |
| 2021-03-31 | $34.55 Million | +59.19% |
| 2020-03-31 | $21.70 Million | +24.22% |
| 2019-03-31 | $17.47 Million | +128.14% |
| 2018-03-31 | $7.66 Million | +40.99% |
| 2017-03-31 | $5.43 Million | -13.75% |
| 2016-03-31 | $6.30 Million | -- |
About China SXT Pharmaceuticals Inc
China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers Advanced TCMP, including Directly-Oral-TCMP, and After-Soaking-Oral TCMP; Fine TCMP and Regular TCMP products; and raw medicinal material, such as SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo,… Read more